Thomas M. Cosgriff

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome

John W. Huggins, C. M. Hsiang, Thomas M. Cosgriff et al. · The Journal of Infectious Diseases · 1991 · 442 citations

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Carlos H. Barrios, Tae Min Kim et al. · Journal of Clinical Oncology · 2014 · 426 citations · Full text

Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes

Roger M. Lyons, Thomas M. Cosgriff, Sanjiv Modi et al. · Journal of Clinical Oncology · 2009 · 271 citations

Low functional and high antigenic antithrombin iii level in a patient with the lupus anticoagulant and recurrent thrombosis

Thomas M. Cosgriff, Barbara A. Martin · Arthritis & Rheumatism · 1981 · 167 citations

Thrombopoiesis, Thrombosis, Venous Thrombosis +14